Rocket Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Election of seven director nominees to hold office until the 2027 annual meeting.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Non-Binding, Advisory Vote on Named Executive Officer Compensation

   ManagementBoard: FOR

   A non-binding, advisory "Say on Pay" vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This proposal asks shareholders to cast a non-binding advisory vote to approve the Company’s named executive officer (NEO) compensation as disclosed in the proxy statement, including the Summary Compensation Table and accompanying narrative. Management is seeking shareholder approval as a governance practice to affirm that the design and outcomes of the compensation program are aligned with stockholder interests; the vote is advisory and does not itself change pay arrangements but is used by the Compensation Committee and Board to inform future decisions. The company emphasizes a pay-for-performance philosophy, significant equity weighting (stock options and RSUs), and a compensation mix intended to align executives’ incentives with long-term value creation while maintaining short-term performance incentives. The proxy notes that the Compensation Committee engages an independent consultant, benchmarks vs. peers, and retains discretion to adjust programs; it also highlights prior strong shareholder support (approximately 98% approval in 2025) as evidence of alignment. Because Rocket is a smaller reporting company, some CD&A-level disclosures are tailored accordingly, but the materials disclose severance/change-in-control protections, incentive plan structure, and clawback and insider trading policies intended to mitigate risk. A vote against would signal investor dissatisfaction and would likely trigger additional engagement and review by the Compensation Committee although it would not compel immediate change; conversely, a vote for provides the Board with a mandate to continue current pay practices. Key governance considerations include the central role of equity (which can create dilution/overhang), use of performance-based incentives, the company’s recent restructuring to preserve cash and focus on core programs, and the Compensation Committee’s use of external benchmarking. For sophisticated analysts evaluating the proposal, material questions include whether realized pay has been driven by long-term shareholder value versus accounting valuation of awards, whether retention and clawback protections are sufficient, and how Say-on-Pay results will influence compensation outcomes in light of recent business events (FDA approval of KRESLADI™, workforce reductions, and strategic refocusing). Overall, management recommends “FOR” arguing that the program strikes an appropriate balance between responsible pay governance and incentives necessary to execute the company’s strategy.

4. 4

   Approval of Stock Option Exchange Program

   ManagementBoard: FOR

   Approve a management-proposed stock option exchange program allowing eligible employees (excludes directors and senior EVP-level officers) to exchange certain underwater options for fewer, replacement options on an approximately value-neutral basis, with new vesting and exercise-price tied to market, intended to restore incentive value and reduce overhang.

   More detail

   The Exchange Proposal requests shareholder approval to implement a stock option exchange program that would allow eligible employees (excluding directors, EVP-level+ officers, consultants and contractors) to exchange outstanding underwater options for fewer replacement options on an approximately value-neutral basis. Management is pursuing shareholder approval because the company’s share price has declined materially from its 2021 highs, leaving a substantial portion of outstanding options deeply underwater and thereby eroding their retention and incentive value; management and the Compensation Committee view an exchange as a more cost-effective and stockholder-aligned way to restore employee incentives than cash raises or fresh equity grants. The program is structured to be approximately value-neutral from an accounting perspective: Exchange Ratios are calibrated so that the fair value of new awards approximates the fair value of surrendered awards, and the number of replacement-option shares is smaller than the number of cancelled-option shares, which should reduce overhang. Key design features include eligibility limited to employees (about 171 as of March 9, 2026) holding options granted prior to 2025 with exercise prices at or above the Threshold Exercise Price, exclusion of directors and senior executives, new vesting schedules for replacement grants, exercise price equal to the trading price at the end of the exchange period, and exchange ratios illustrated to range roughly from 1.59:1 to 3.57:1 across exercise-price bands. The Board and Compensation Committee recommend the program as a retention tool and a means to reduce outstanding, likely never-to-be-exercised options, while avoiding near-term cash expenditures or large new equity grants; they also note potential reduction in reported compensation expense over time. Material risks and considerations for sophisticated analysts include potential dilution if replacement options are later exercised, the degree to which the exchange is truly value-neutral under different volatility/term assumptions, the limited scope of eligible participants (which excludes senior leaders who hold a majority of options), and the possibility of negative investor reaction if perceived as management-friendly or as enabling re-pricing without sufficient governance protections. The proposal also requires careful review of accounting treatment, tax consequences, and tender-offer mechanics; the company notes it will file a Schedule TO and that the Board retains discretion to amend or cancel the program even if commenced. On balance, the Board’s rationale emphasizes restoring incentives to a broad employee population, reducing overhang, and using a structured, consultant-supported approach to preserve stockholder value, and therefore recommends a vote FOR.

Upcoming shareholder meetings at Rocket Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Rocket Pharmaceuticals Inc 2026 annual meeting?

Rocket Pharmaceuticals Inc (RCKT) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.

What is the record date for the Rocket Pharmaceuticals Inc 2026 meeting?

The record date for the Rocket Pharmaceuticals Inc 2026 meeting is Tuesday, March 24, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Rocket Pharmaceuticals Inc's 2026 meeting?

The board is presenting 7 director nominees at the Rocket Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Rocket Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Rocket Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.